- Previous Close
0.0080 - Open
0.0090 - Bid 0.0080 x --
- Ask 0.0090 x --
- Day's Range
0.0080 - 0.0090 - 52 Week Range
0.0040 - 0.0140 - Volume
2,408,393 - Avg. Volume
3,257,509 - Market Cap (intraday)
14.168M - Beta (5Y Monthly) 0.97
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Feb 24, 2025 - Feb 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company primarily develops Felix, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid oxidative stress assay; and AI-Port. In addition, the company offers ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
www.memphasys.comRecent News: MEM.AX
View MorePerformance Overview: MEM.AX
Trailing total returns as of 1/16/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MEM.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MEM.AX
View MoreValuation Measures
Market Cap
14.17M
Enterprise Value
18.70M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
308.06
Price/Book (mrq)
2.07
Enterprise Value/Revenue
311.66
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.88%
Return on Equity (ttm)
-62.47%
Revenue (ttm)
1.09M
Net Income Avi to Common (ttm)
-4.44M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
277.8k
Total Debt/Equity (mrq)
70.33%
Levered Free Cash Flow (ttm)
-2.5M